Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) saw a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 232,078 shares, a growth of 414.3% from the July 30th total of 45,127 shares. Currently, 2.9% of the company’s shares are short sold. Based on an average trading volume of 994,693 shares, the days-to-cover ratio is presently 0.2 days.

Evogene Trading Up 0.9%

Shares of EVGN stock traded up $0.01 during mid-day trading on Friday, reaching $0.54. The stock had a trading volume of 10,097 shares, compared to its average volume of 910,478. The stock’s 50-day moving average price is $0.53 and its two-hundred day moving average price is $0.69. Evogene has a 52-week low of $0.37 and a 52-week high of $1.50. The firm has a market capitalization of $4.73 million, a PE ratio of -0.60 and a beta of 1.40.

Insiders Place Their Bets

In related news, Director Leon Recanati purchased 460,000 shares of Evogene stock in a transaction that occurred on Tuesday, August 11th. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $294,400.00. Following the transaction, the director directly owned 1,343,886 shares in the company, valued at $860,087.04. The trade was a 52.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in Evogene in the 4th quarter worth approximately $25,000. Jane Street Group LLC increased its stake in shares of Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares during the period. Finally, Citadel Advisors LLC raised its holdings in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares in the last quarter. Institutional investors own 10.40% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.